Recruiting

Maolactin FMR Supplementation for Exercise Recovery and Muscle Comfort in Adults Over 45

Study Aim

This study aims to evaluate whether Maolactin FMR supplementation can improve exercise recovery and muscle comfort by reducing inflammation in adults over 45.

What is being tested

Maolactin

+ Maltodextrin

Drug

Who is being recruted

Joint Diseases+9

+ Muscular Diseases

+ Musculoskeletal Diseases

Over 45 Years

+21 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Treatment Study

Placebo-ControlledPhase 3

Interventional

Study Start: February 2025

See protocol details

Summary

Principal SponsorRDC Clinical Pty Ltd

Study ContactAmanda Rao, PhDMore contacts

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: February 27, 2025

Actual date on which the first participant was enrolled.

This study is designed to explore the effects of a supplement called Maolactin FMR on exercise recovery, inflammation, and muscle comfort. It targets adults over the age of 45 who are otherwise healthy but may experience issues like chronic inflammation, mobility challenges, and muscle or joint discomfort. This research is important because it seeks to discover whether this supplement can help improve these common problems, potentially offering a natural way to enhance quality of life for older adults. The study is part of a larger research effort and is conducted in a way that ensures neither the participants nor the researchers know who is receiving the supplement or a placebo, which helps ensure unbiased results. Participants in the study will take Maolactin FMR or a placebo for eight weeks as part of a ten-week study period. The study is structured to closely monitor changes in participants' inflammation levels, mobility, and any muscle or joint pain they may experience. By comparing results from those taking the supplement to those taking a placebo, the study aims to measure the supplement's effectiveness. Although no specific risks or benefits are detailed, the study's setup helps ensure safety and reliability in its findings.

Official TitleEffect of Maolactin™ FMR Supplementation on Exercise Recovery, Inflammation, and Muscle Comfort in an Otherwise Healthy Population: A Double-blind Randomized Placebo-controlled Study

NCT06444763

Principal SponsorRDC Clinical Pty Ltd

Study ContactAmanda Rao, PhDMore contacts

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

100 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 45 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Joint DiseasesMuscular DiseasesMusculoskeletal DiseasesNervous System DiseasesNeurologic ManifestationsNeuromuscular DiseasesPainSigns and SymptomsPathological Conditions, Signs and SymptomsArthralgiaMusculoskeletal PainMyalgia

Criteria

8 inclusion criteria required to participate

BMI 25.0 - 35.0 kg/m2

C-reactive protein (CRP) equal to or greater than 2.0 mg/L

Generally healthy

Adults 45 years and older

Show More Criteria

13 exclusion criteria prevent from participating

Pregnant or lactating women

Chronic past and/or current alcohol use (\>21 alcoholic drinks per week)

Receiving medications known to affect inflammation such as steroids

Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or other anticoagulation therapy including low dose aspirin

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental

2 capsules containing a total of 500 mg/day active proteins taken once daily before the morning meal

Group II

Placebo

2 capsules containing maltodextrin (0mg/day active proteins) taken once daily before the morning meal

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

RDC Clinical Pty Ltd

Brisbane, AustraliaOpen RDC Clinical Pty Ltd in Google Maps

Recruiting

One Study Center